Literature DB >> 8628496

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group.

D McGuire1, L Garrison, C Armon, R Barohn, W Bryan, R Miller, G Parry, J Petajan, M Ross.   

Abstract

The Tufts Quantitative Neuromuscular Exam (TQNE) is a standardized tool for measuring muscle strength and pulmonary function in patients with amyotrophic lateral sclerosis (ALS). We describe the relationship of TQNE scores to functional disability and health-related quality of life as measured by the Sickness Impact Profile (SIP) in 524 ALS patients. There was a significant relationship (p < 0.0001) between TQNE and SIP scores, both in cross section and over time. TQNE scores strongly relate to ALS patients' quality of life and ability to perform activities of daily living.

Entities:  

Mesh:

Year:  1996        PMID: 8628496     DOI: 10.1212/wnl.46.5.1442

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Assessing individual quality of life in amyotrophic lateral sclerosis.

Authors:  S Clarke; A Hickey; C O'Boyle; O Hardiman
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

Review 2.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

3.  Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.

Authors:  S J Ackerman; E M Sullivan; K M Beusterien; H M Natter; D F Gelinas; D L Patrick
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

Review 4.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Authors:  Robert G Miller; J D Mitchell; Dan H Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

Review 5.  Patient-Perceived Outcomes and Quality of Life in ALS.

Authors:  Zachary Simmons
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 6.  Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.

Authors:  Eleanor James; Cathy Ellis; Ruth Brassington; Sivakumar Sathasivam; Carolyn A Young
Journal:  Cochrane Database Syst Rev       Date:  2022-05-20

7.  SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy.

Authors:  John T Kissel; Bakri Elsheikh; Wendy M King; Miriam Freimer; Charles B Scott; Stephen J Kolb; Sandra P Reyna; Thomas O Crawford; Louise R Simard; Kristin J Krosschell; Gyula Acsadi; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan Sorenson; Jo Anne Maczulski; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2014-02       Impact factor: 3.217

Review 8.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.